	Intended Result	Your Report	Your Score
Specimen 8272	HBsAg positive	HBsAg positive	2
	HCV Ag/Ab negative	HCV Ag/Ab negative	2
	HIV 1/2 Ag/Ab negative	HIV 1/2 Ag/Ab negative	2
Specimen 8273	HBsAg negative	HBsAg negative	2
	HCV Ag/Ab negative	HCV Ag/Ab negative	2
	HIV 1/2 Ag/Ab presumptive positive	HIV 1/2 Ag/Ab presumptive positive	2
Specimen 8274	HBsAg negative	HBsAg negative	2
	HCV Ag/Ab positive	HCV Ag/Ab positive	2
	HIV 1/2 Ag/Ab negative	HIV 1/2 Ag/Ab negative	2

Cumulative score information
Total number of specimens sent to you for **UK NEQAS for Blood borne viruses** over the last 6 distribution is 18
For these distributions specimen numbers 7731 7732 7733 7880 7881 7882 7979 7980 7981 8072 8073 8074 8164 8165 8166 8272 8273 8274 have been sent.
Number of specimens reported too late for analysis (not scored) 0
Your cumulative score for the specimen/test combinations that you reported was 108 out of a possible total of 108
The mean score calculated from the reports returned by **UK** laboratories testing the specimen/test combinations you examined was 107.51 (with a standard error of 1.63).

Performance rating
Your performance rating for **UK NEQAS for Blood borne viruses** (i.e. the number of standard errors by which your cumulative score lies above or below the mean for **UK** laboratories) is **0.30.**
A performance rating of more than 1.96 standard errors below the mean indicates possible poor performance.
Your performance rating may change if other participants' results are amended.
No score penalty is incurred for non return of reports. However non return of results may be used as a measure of poor performance.





Comments

Overall performance for this distribution was outstanding with 100% of participants returning the intended results for HBsAg and HCV Ag/Ab, and 98.4% of participants returning the intended results for HIV-1/2 Ag/Ab.

This scheme is intended for laboratories performing screening assays. Results of confirmatory assays (e.g. immunoblot assays) are not included in the analysis.

Please see comments page 5 for scheme specific information

In the histograms on page 2 and subsequent pages a maximum of 12 kit/test method results are displayed. These include the most commonly used methods and the method(s) used in your laboratory indicated by an arrow(s). The figures in the histograms and those in the overall results tables may differ (1) due to exclusion of kits displayed in the histograms resulting in apparently lower numbers of data sets in the histograms or (2) due to participants using more than one kit resulting in higher numbers of data sets in the histograms.

Turn around time: The time taken to report your results was 0-days. This information is provided for your own use and does not form part of your performance assessment.

Enquiries: For repeat specimens in case of an EQA failure investigation, please request using the web form at **https://ukneqasmicro.org.uk/participant-info/order-repeat-specimens/.**

Pre-distribution test results are available should you experience a technical failure and wish to discuss the results. Any queries about this distribution can be addressed to Dr Sanjiv Rughooputh at organiser@ukneqasmicro.org.uk.

Acknowledgments
We thank colleagues at UKHSA Manchester, UKHSA Virus Reference Division in Colindale, NHSBT, St George's Hospital, and the Department of Microbiology at Gloucestershire Hospitals for their assistance with pre-distribution testing.

Report authorised by: Dr Sanjiv Rughooputh, Scheme Organiser.

Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:01 on Wednesday 27 March 2024

Three specimens derived from thrombinised human plasma (serum) donations were dispatched with a request to report on the presence of hepatitis B surface antigen (HBsAg), hepatitis C antigen/antibody and HIV-1/2 antigen/antibody. Specimens 8272, 8273 and 8274 were diluted 9.6, 17.1 and 4.8, respectively. Positive neat materials used to prepare HBsAg positive specimens were screened negative for HBeAg. Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8272

Intended result
HBsAg positive



	UK	(%)	All	(%)
Dia.Pro	1	(1.2)	1	(0.9)
Roche	11	(12.8)	12	(10.7)
Siemens:Atellica IM	1	(1.2)	2	(1.8)
BioRad	1	(1.2)	2	(1.8)
Murex	3	(3.5)	4	(3.6)
Siemens:ADVIA Centaur	4	(4.7)	5	(4.5)
Roche : Elecsys	7	(8.1)	8	(7.1)
Roche : Cobas analyser	8	(9.3)	9	(8.0)
DiaSorin : Liaison	9	(10.5)	12	(10.7)
Abbott : Architect	10	(11.6)	13	(11.6)
Abbott: Alinity	11	(12.8)	18	(16.1)
bioMerieux : Vidas	16	(18.6)	19	(17.0)

Your Report : HBsAg positive
Your Score : **2**

Overall Results	UK	All	Score
HBsAg positive	45	83	2
HBsAg equivocal	0	0	1
HBsAg negative	0	0	-1
Total	45	83	
% Correct	100	100	

Specimen : 8272

Intended result
HCV Ag/Ab negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.1)
Roche	11	(14.7)	12	(12.9)
Beckman : Access	2	(2.7)	2	(2.2)
Liaison : XL	2	(2.7)	2	(2.2)
BioRad	3	(4.0)	3	(3.2)
Siemens:ADVIA Centaur	4	(5.3)	5	(5.4)
Roche : Elecsys	6	(8.0)	7	(7.5)
bioMerieux : Vidas	7	(9.3)	7	(7.5)
Roche : Cobas analyser	8	(10.7)	9	(9.7)
DiaSorin : Liaison	6	(8.0)	9	(9.7)
Abbott : Architect	11	(14.7)	14	(15.1)
Abbott: Alinity	9	(12.0)	16	(17.2)

Your Report : HCV Ag/Ab negative
Your Score : **2**

Overall Results	UK	All	Score
HCV Ag/Ab positive	0	0	-1
HCV Ag/Ab equivocal	0	0	1
HCV Ag/Ab negative	44	81	2
Total	44	81	
% Correct	100	100	

Specimen : 8272

Intended result
HIV-1/2 Ag/Ab negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.0)
Roche	14	(17.7)	15	(15.3)
Siemens:Atellica IM	1	(1.3)	2	(2.0)
Beckman : Access	2	(2.5)	2	(2.0)
Murex : HIV Ag/Ab	1	(1.3)	2	(2.0)
Siemens:ADVIA Centaur	4	(5.1)	5	(5.1)
Roche : Elecsys	4	(5.1)	5	(5.1)
Roche : Cobas analyser	8	(10.1)	9	(9.2)
DiaSorin : Liaison	7	(8.9)	10	(10.2)
bioMerieux : Vidas	12	(15.2)	12	(12.2)
Abbott : Architect	10	(12.7)	13	(13.3)
Abbott: Alinity	10	(12.7)	17	(17.3)

Your Report : HIV 1/2 Ag/Ab negative
Your Score : **2**

Overall Results	UK	All	Score
HIV 1/2 Ag/Ab positive	1	2	-1
HIV 1/2 Ag/Ab equivocal	2	2	1
HIV 1/2 Ag/Ab negative	42	79	2
Total	45	83	
% Correct	93.3	95.2	

Published at 10:01 on Wednesday 27 March 2024

Three specimens derived from thrombinised human plasma (serum) donations were dispatched with a request to report on the presence of hepatitis B surface antigen (HBsAg), hepatitis C antigen/antibody and HIV-1/2 antigen/antibody. Specimens 8272, 8273 and 8274 were diluted 9.6, 17.1 and 4.8, respectively. Positive neat materials used to prepare HBsAg positive specimens were screened negative for HBeAg. Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8273

Intended result
HBsAg negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.0)
Roche	11	(14.1)	12	(12.4)
Abbott	1	(1.3)	1	(1.0)
Siemens:Atellica IM	1	(1.3)	2	(2.1)
Murex	2	(2.6)	3	(3.1)
Siemens:ADVIA Centaur	4	(5.1)	5	(5.2)
Roche : Elecsys	7	(9.0)	8	(8.2)
Roche : Cobas analyser	8	(10.3)	9	(9.3)
DiaSorin : Liaison	9	(11.5)	12	(12.4)
bioMerieux : Vidas	12	(15.4)	12	(12.4)
Abbott : Architect	9	(11.5)	12	(12.4)
Abbott: Alinity	10	(12.8)	17	(17.5)

Your Report : HBsAg negative
Your Score : **2**

Overall Results	UK	All	Score
HBsAg positive	0	0	-1
HBsAg equivocal	0	0	1
HBsAg negative	45	83	2
Total	45	83	
% Correct	100	100	

Specimen : 8273

Intended result
HCV Ag/Ab negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.1)
Roche	11	(14.5)	12	(12.8)
Beckman : Access	2	(2.6)	2	(2.1)
Liaison : XL	2	(2.6)	2	(2.1)
BioRad	3	(3.9)	3	(3.2)
Siemens:ADVIA Centaur	4	(5.3)	5	(5.3)
Roche : Elecsys	6	(7.9)	7	(7.4)
bioMerieux : Vidas	8	(10.5)	8	(8.5)
Roche : Cobas analyser	8	(10.5)	9	(9.6)
DiaSorin : Liaison	6	(7.9)	9	(9.6)
Abbott : Architect	11	(14.5)	14	(14.9)
Abbott: Alinity	9	(11.8)	16	(17.0)

Your Report : HCV Ag/Ab negative
Your Score : **2**

Overall Results	UK	All	Score
HCV Ag/Ab positive	0	0	-1
HCV Ag/Ab equivocal	0	0	1
HCV Ag/Ab negative	44	81	2
Total	44	81	
% Correct	100	100	

Specimen : 8273

Intended result
HIV-1/2 Ag/Ab presumptive positive



	UK	(%)	All	(%)
Dia.Pro	1	(1.2)	1	(0.9)
Roche	13	(15.7)	14	(13.1)
BioRad : Genscreen	0	(0.0)	2	(1.9)
Beckman : Access	2	(2.4)	2	(1.9)
Murex : HIV Ag/Ab	1	(1.2)	2	(1.9)
Siemens:ADVIA Centaur	4	(4.8)	5	(4.7)
Roche : Elecsys	4	(4.8)	5	(4.7)
Roche : Cobas analyser	8	(9.6)	9	(8.4)
DiaSorin : Liaison	8	(9.6)	11	(10.3)
Abbott : Architect	10	(12.0)	13	(12.1)
Abbott: Alinity	10	(12.0)	17	(15.9)
bioMerieux : Vidas	16	(19.3)	18	(16.8)

Your Report : HIV 1/2 Ag/Ab presumptive positive
Your Score : **2**

Overall Results	UK	All	Score
HIV 1/2 Ag/Ab positive	44	82	2
HIV 1/2 Ag/Ab equivocal	0	0	1
HIV 1/2 Ag/Ab negative	0	0	-1
Total	44	82	
% Correct	100	100	

Published at 10:01 on Wednesday 27 March 2024

Three specimens derived from thrombinised human plasma (serum) donations were dispatched with a request to report on the presence of hepatitis B surface antigen (HBsAg), hepatitis C antigen/antibody and HIV-1/2 antigen/antibody. Specimens 8272, 8273 and 8274 were diluted 9.6, 17.1 and 4.8, respectively. Positive neat materials used to prepare HBsAg positive specimens were screened negative for HBeAg. Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8274

Intended result
HBsAg negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.0)
Roche	11	(14.1)	12	(12.4)
Abbott	1	(1.3)	1	(1.0)
Siemens:Atellica IM	1	(1.3)	2	(2.1)
Murex	2	(2.6)	3	(3.1)
Siemens:ADVIA Centaur	4	(5.1)	5	(5.2)
Roche : Elecsys	7	(9.0)	8	(8.2)
Roche : Cobas analyser	8	(10.3)	9	(9.3)
DiaSorin : Liaison	9	(11.5)	12	(12.4)
bioMerieux : Vidas	12	(15.4)	12	(12.4)
Abbott : Architect	9	(11.5)	12	(12.4)
Abbott: Alinity	10	(12.8)	17	(17.5)

Your Report : HBsAg negative
Your Score : **2**

Overall Results	UK	All	Score
HBsAg positive	0	0	-1
HBsAg equivocal	0	0	1
HBsAg negative	45	83	2
Total	45	83	
% Correct	100	100	

Specimen : 8274

Intended result
HCV Ag/Ab positive



	UK	(%)	All	(%)
Dia.Pro	1	(1.2)	1	(0.9)
Roche	11	(13.4)	12	(11.2)
Beckman : Access	2	(2.4)	2	(1.9)
BioRad	3	(3.7)	3	(2.8)
Liaison : XL	2	(2.4)	3	(2.8)
Siemens:ADVIA Centaur	4	(4.9)	5	(4.7)
Roche : Elecsys	6	(7.3)	7	(6.5)
Roche : Cobas analyser	8	(9.8)	9	(8.4)
DiaSorin : Liaison	6	(7.3)	9	(8.4)
Abbott : Architect	11	(13.4)	14	(13.1)
bioMerieux : Vidas	12	(14.6)	15	(14.0)
Abbott: Alinity	10	(12.2)	17	(15.9)

Your Report : HCV Ag/Ab positive
Your Score : **2**

Overall Results	UK	All	Score
HCV Ag/Ab positive	44	81	2
HCV Ag/Ab equivocal	0	0	1
HCV Ag/Ab negative	0	0	-1
Total	44	81	
% Correct	100	100	

Specimen : 8274

Intended result
HIV-1/2 Ag/Ab negative



	UK	(%)	All	(%)
Dia.Pro	1	(1.3)	1	(1.0)
Roche	14	(17.7)	15	(15.3)
Siemens:Atellica IM	1	(1.3)	2	(2.0)
Beckman : Access	2	(2.5)	2	(2.0)
Murex : HIV Ag/Ab	1	(1.3)	2	(2.0)
Siemens:ADVIA Centaur	4	(5.1)	5	(5.1)
Roche : Elecsys	4	(5.1)	5	(5.1)
Roche : Cobas analyser	8	(10.1)	9	(9.2)
DiaSorin : Liaison	7	(8.9)	10	(10.2)
bioMerieux : Vidas	12	(15.2)	12	(12.2)
Abbott : Architect	10	(12.7)	13	(13.3)
Abbott: Alinity	10	(12.7)	17	(17.3)

Your Report : HIV 1/2 Ag/Ab negative
Your Score : **2**

Overall Results	UK	All	Score
HIV 1/2 Ag/Ab positive	0	0	-1
HIV 1/2 Ag/Ab equivocal	0	0	1
HIV 1/2 Ag/Ab negative	45	83	2
Total	45	83	
% Correct	100	100	

Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:01 on Wednesday 27 March 2024

Comments on distribution 5522

Overall performance in this distribution was excellent, with 99.4% of participants reporting the intended results. This is a slight improvement of 0.1% on the previous distribution 5488, where the overall performance was 99.3%.

Eighty-seven sets of specimens were dispatched with 83 participants returning results: representing a return rate of 95.4%. Compared to distribution 5488; where the return rate was 93.1%, this is an improvement of 2.3%.

Participants are requested to provide more details on the methods they use in order to have better platform groupings. This information is very helpful for troubleshooting in case of kit/ platform issues.

Participants who did not obtain the intended results are requested to investigate and report the plausible root cause by completing an incident review form (IRF) online within 30 days of this report being published.

Non return of results without a valid reason is considered as poor performance and should also be reported in a similar manner.

IRFs are taken into considerations when poor performance analysis is carried out for the National Quality Assurance Advisory Panel (NQAAP). IRFs can be completed on the following link: https://uknegasmicro.org.uk/incident-review-form

---

End of report

Operated by UK Health Security Agency
61 Colindale Avenue
Colindale
London NW9 5EQ

UK NEQAS for Microbiology
PO Box 63003
London NW9 1GH

Published at 10:01 on Wednesday 27 March 2024